Pinocembrin Shows Dual Kidney Protection in Diabetic Mouse and Cell Models

A flavonoid found in propolis and many plants has shown protective effects against kidney damage in both diabetic mice and high-glucose-treated kidney cells, according to a study published in Applied Biological Chemistry. The compound, pinocembrin, appears to act through two distinct molecular pathways: one guarding the kidney’s tubules against inflammation and scarring, and another restraining overgrowth of cells in the glomeruli, the blood-filtering units destroyed by diabetic kidney disease. The work combined computer-based target prediction with experiments in db/db mice, a standard model of type 2 diabetes, and in cultured human kidney cells exposed to high sugar concentrations.

Diabetic nephropathy, the leading global cause of end-stage renal disease, damages the kidney along two parallel fronts. In the glomeruli, mesangial cells proliferate and deposit excess matrix, thickening and stiffening the filtering barrier. In the tubules and surrounding interstitium, chronic inflammation drives fibrosis, the accumulation of collagen that progressively chokes off functional tissue. Because these two compartments interact and reinforce each other’s decline, therapies that address only one front often fail to halt disease progression. The researchers set out to test whether pinocembrin, previously reported to have antioxidant, anti-inflammatory, and neuroprotective properties, could act on both fronts simultaneously.

The team began with a network pharmacology approach, mining four databases—TCMSP, CTD, Swiss Target Prediction, and SymMap—for proteins that pinocembrin might bind. After removing duplicates and standardizing gene names, 168 unique candidate targets remained. They then cross-referenced these targets against gene expression data from the public GEO dataset GSE30122, which contains glomerular and tubular samples from patients with diabetic nephropathy and healthy individuals. In tubular tissue, differential expression analysis identified 690 down-regulated and 141 up-regulated genes, of which 17 overlapped with pinocembrin’s predicted targets. In glomerular tissue, 146 genes were down-regulated and 564 up-regulated, with 11 overlapping the compound’s target list.

Protein interaction network analysis of these overlaps pointed to compartment-specific hub proteins. In the tubular network, CASP3, HSP90AB1, and VIM emerged as the most connected nodes, with HSP90AB1 showing both a high degree of connectivity and the strongest predicted binding to pinocembrin in molecular docking simulations. In the glomerular network, the hubs were ALB, PDGFRB, and KDR—the latter also known as vascular endothelial growth factor receptor 2, or VEGFR2, a receptor central to glomerular endothelial function and mesangial cell proliferation. Enrichment analyses linked the tubular targets to cellular stress responses and the glomerular targets to VEGF signaling, giving the team concrete pathways to test experimentally.

Molecular docking provided computational support for these interactions. Pinocembrin docked against six candidate proteins, with LibDockScores of −122.127 for HSP90AB1, −100.362 for CASP3, −88.866 for VIM, −96.984 for ALB, −106.926 for KDR, and −104.682 for PDGFRB, each accompanied by identifiable hydrogen bonds and residue contacts. The authors caution, however, that these are predictions only; direct physical binding of pinocembrin to any of these targets has not yet been demonstrated and would require techniques such as surface plasmon resonance or cellular thermal shift assays.

The in vivo arm of the study used seven-week-old male db/db mice on a C57BLKS/J background, divided into three groups of eight: non-diabetic db/m controls, untreated db/db mice, and db/db mice given pinocembrin at 20 mg/kg by daily gavage for four weeks. By the end of the intervention, treated mice showed markedly lower serum levels of blood urea nitrogen, creatinine, and microalbumin than their untreated diabetic counterparts. Histological staining revealed that pinocembrin eased glomerular hypertrophy, tubular edema, interstitial collagen deposition, and mesangial matrix accumulation. Western blotting of kidney tissue showed that the diabetes-driven rise in p-Smad2/3, TGF-β1, and α-SMA—core effectors of renal fibrosis—was significantly blunted by the compound.

In vitro experiments probed the tubular mechanism in human HK-2 proximal tubule cells exposed to 30 mM glucose. Because pinocembrin proved toxic above 50 micromolar in these cells, the team selected working concentrations of 5, 10, and 20 micromolar. At these doses, pinocembrin dose-dependently reversed the high-glucose-induced upregulation of fibrotic markers and suppressed the inflammatory cytokines IL-1β, IL-6, and TNF-α, both inside the cells and in their culture supernatants as measured by ELISA. Crucially, the same treatment reduced the expression of HSP90AB1, TGF-β1, and phosphorylated Smad2/3, and pinocembrin also lowered HSP90AB1 levels in the kidneys of the db/db mice, supporting the relevance of this axis beyond the dish.

The glomerular side of the story unfolded in SV40 mesangial cells grown in 45 mM glucose. Pinocembrin again reversed the glucose-driven accumulation of fibronectin and collagen IV, key extracellular matrix components of glomerular sclerosis. EdU incorporation assays showed that high glucose dramatically increased mesangial cell proliferation and that pinocembrin co-treatment sharply reduced it. On the signaling level, high glucose raised VEGFR expression and ERK phosphorylation, and pinocembrin suppressed both in a dose-dependent manner without affecting total ERK. Consistent with the cell data, VEGFR was elevated in db/db mouse kidneys and reduced by pinocembrin treatment, tying the in vitro pathway to the living animal.

The authors frame their findings as the first delineation of pinocembrin’s compartment-specific actions in diabetic nephropathy and the first link between the compound and the HSP90AB1/TGF-β1/Smad2/3 and VEGFR/ERK axes. They also acknowledge substantial limitations. All mechanistic validation was performed in vitro, in models that cannot reproduce the immune infiltration, cell–cell interactions, and systemic metabolic disturbances of diabetic kidneys in a living body. Direct binding of pinocembrin to HSP90AB1 or VEGFR remains unconfirmed, gain- or loss-of-function studies are needed to prove these targets are genuinely required for the protective effects, and no pharmacokinetic or pharmacodynamic data exist for pinocembrin in diabetic nephropathy. Potential synergy with existing drugs such as SGLT2 inhibitors and GLP-1 receptor agonists is also untested.

For now, the results position pinocembrin as a candidate functional-food ingredient warranting further preclinical development rather than a proven therapy. The study establishes an experimental foundation—dual compartment protection, two candidate molecular targets, and a reproducible dosing regimen in mice—but the path from a 20 mg/kg mouse gavage dose to any human application runs through pharmacokinetic profiling, target validation, and combination studies that have yet to be done. What the work does deliver is a concrete molecular map: one flavonoid, two renal compartments, and two signaling pathways whose suppression tracked with healthier kidneys in a diabetic animal model.

Subject of Research: Preclinical evaluation of pinocembrin's dual protective mechanisms against tubular fibrosis and glomerular mesangial lesions in diabetic nephropathy

Article Title: Pinocembrin alleviates tubular inflammatory fibrosis and glomerular mesangial lesions in diabetic nephropathy through HSP90AB1/TGF-β1/Smad3 and VEGFR/ERK signaling

Article References: Wang, Y., Wang, J., Cai, M., Ren, J., Jia, F., Jiang, W., Su, D., Yang, H., & Chen, G. (2026). Pinocembrin alleviates tubular inflammatory fibrosis and glomerular mesangial lesions in diabetic nephropathy through HSP90AB1/TGF-β1/Smad3 and VEGFR/ERK signaling. Applied Biological Chemistry, 69(1), Article 68. https://doi.org/10.1186/s13765-026-01136-8

Image Credits: AI Generated

DOI: 10.1186/s13765-026-01136-8

Keywords: pinocembrin, diabetic nephropathy, HSP90AB1, TGF-beta1, Smad3, VEGFR, ERK signaling, db/db mice, HK-2 cells, mesangial cells, renal fibrosis, network pharmacology